Mouse Genome Informatics
cn
    Nf2tm2Gth/Nf2tm2Gth
Trp53tm1Brn/Trp53tm1Brn

involves: 129P2/OlaHsd * 129S7/SvEvBrd
Key:
phenotype observed in females WTSI Wellcome Trust Sanger Institute
phenotype observed in males EuPh Europhenome
N normal phenotype
       
mortality/aging
• following adenoviral cre treatment, median survival time is 135 days

tumorigenesis
• following adenoviral cre treatment, 86% of mice develop thoracic tumors (including malignant mesotheliomas, 45 of 55; rhabdomyosarcomas, 2 of 55; and schwannomas, 1 of 55)
• following adenoviral cre treatment, mice develop either non-aggressive epitheloid or mixed tumors with confined invasion of the visceral pleural or (sarcomatoid) tumors with strong invasion of visceral and parietal pleura
• following adenoviral cre treatment, 4% of mice develop hepatomegaly either due to oval cell hyperplasia, cholangio-carcinomas and/or hepatomas, and leiomyomas of the uterus
• following adenoviral cre treatment, 11% of mice develop aspecific tumors not induced by adeno-cre treatment
• following adenoviral cre treatment, latency to developing malignant mesotheliomas is lower than in mice carrying other combinations of Cdkn2atm2Brn, Nf2tm2Gth, and Trp53tm1Brn alleles
• in 7% of mice following adenoviral cre treatment (J:132943)
• following adenoviral cre treatment, 7% mice develop monocytic myeloid leukemias
• a few following adenoviral cre treatment
• following adenoviral cre treatment, latency to developing malignant mesotheliomas is lower than in mice carrying other combinations of Cdkn2atm2Brn, Nf2tm2Gth, and Trp53tm1Brn alleles

liver/biliary system
• following adenoviral cre treatment, 4% of mice develop hepatomegaly either due to oval cell hyperplasia, cholangio-carcinomas and/or hepatomas, and leiomyomas of the uterus

Mouse Models of Human Disease
OMIM IDRef(s)
Mesothelioma, Malignant; MESOM 156240 J:132943